The idea of glucose-responsive insulin has been bandied about for decades. Could a new insulin formulation automatically level out high and low glucose levels such that a person dependent on insulin only needed to take one shot a day? Now CEO Mike Moradi has assembled a team with the experience necessary to make this dream a reality — and at an accessible price point.